Analysis of the effects of a two-year course of allergen-specific immunotherapy in children with atopic dermatitis and sensitization to house dust mites
DOI:
https://doi.org/10.15574/SP.2022.127.59Keywords:
sublingual immunotherapy, atopic dermatitis, house dust mite, childrenAbstract
Atopic dermatitis is a chronic inflammatory skin disease that affects 15% to 30% of children and 2% to 10% of adults worldwide. Some observations suggest that allergens may be an important cause of atopic dermatitis. Allergen-specific immunotherapy can reduce symptoms in people with atopic dermatitis by suppressing abnormal immune responses to allergens.
Purpose - to evaluate the role of sublingual immunotherapy in the treatment of atopic dermatitis in children with sensitization to house dust mite, by conducting a randomized 24-month clinical trial with house dust mite extract.
Materials and methods. The study included 26 children with atopic dermatitis, sensitized to house dust mites. 12 patients received sublingual immunotherapy and 14 patients received only symptomatic treatment (the control group). The disease activity of atopic dermatitis was evaluated using the dynamics of SCORAD indicators and the CDLQI questionnaire.
Results. After 24 months from the start of treatment, the decrease in SCORAD was 52.1% in the sublingual immunotherapy group (Wilcoxon T-test, T-W=78.0; p<0.001) and 20.2% in the control group. The decrease in CDLQI after 24 months was 40% in the sublingual immunotherapy group (T-W=66.0; p<0.001), in the control group no improvement was found. We have not found influence of age and degree of severity on the effectiveness of therapy.
Conclusions. This randomized 2-year study showed that sublingual immunotherapy with house dust mite extract can provide significant clinical efficacy according to SCORAD and CDLQI questionnaire in children with atopic dermatitis.
The research was carried out in accordance with the principles of the Helsinki Declaration. The study protocol was approved by the Local Ethics Committee of the participating institution. The informed consent of the patient was obtained for conducting the studies.
No conflict of interests was declared by the author.
References
Bumbacea RS, Corcea SL, Ali S, Dinica LC, Fanfaret IS, Boda D. (2020). Mite allergy and atopic dermatitis: Is there a clear link? (Review). Experimental and therapeutic medicine. 20 (4): 3554-3560. https://doi.org/10.3892/etm.2020.9120; PMid:32905207 PMCid:PMC7465295
Burks AW, Calderon MA, Casale T, Cox L, Demoly P, Jutel M, Nelson H, Akdis CA. (2013). Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. J Allergy Clin Immunol. 131 (5): 1288-1296. https://doi.org/10.1016/j.jaci.2013.01.049; PMid:23498595
Canonica GW, Ansotegui IJ, Pawankar R, Schmid-Grendelmeier P, van Hage M et al. (2013). A WAO - ARIA - GA²LEN consensus document on molecular-based allergy diagnostics. The World Allergy Organization journal. 6 (1): 17. https://doi.org/10.1186/1939-4551-6-17; PMid:24090398 PMCid:PMC3874689
González-Pérez R, Poza-Guedes P, Pineda F, Castillo M, Sánchez-Machín I. (2021). House Dust Mite Precision Allergy Molecular Diagnosis (PAMD@) in the Th2-prone Atopic Dermatitis Endotype. Life (Basel, Switzerland). 11 (12): 1418. https://doi.org/10.3390/life11121418; PMid:34947948 PMCid:PMC8705438
Huang C, Tang J. (2022). Sublingual immunotherapy with Dermatophagoides farinae drops for pediatric atopic dermatitis. Int J Dermatol. 61 (2): 246-251. https://doi.org/10.1111/ijd.15977; PMid:34792188
Mozyrska O. (2022). Efficacy of allergen-specific immunotherapy in children with atopic dermatitis sensitized to house dust mites. Child's health. 17; 2: 85-90. https://doi.org/10.22141/2224-0551.17.2.2022.1499
Mozyrska OV. (2022). The tol-like receptor 2 polymorphism significance for the development of sensitization to house dust mites in children with atopic dermatitis. Modern Pediatrics. Ukraine. 4(124): 60-64. https://doi.org/10.15574/SP.2022.124.60
Muraro A, Roberts G, Halken S, Agache I, Angier E et al. (2018). EAACI guidelines on allergen immunotherapy: Executive statement. Allergy. 73 (4): 739-743. https://doi.org/10.1111/all.13420; PMid:29380390
Qin YE, Mao JR, Sang YC, Li WX. (2014). Clinical efficacy and compliance of sublingual immunotherapy with Dermatophagoides farinae drops in patients with atopic dermatitis. Int J Dermatol. 53: 650-655. https://doi.org/10.1111/ijd.12302; PMid:23968339
Slavyanakaya TA, Derkach VV, Sepiashvili RI. (2016). Debates in allergy medicine: specific immunotherapy efficiency in children with atopic dermatitis. World Allergy Organ J. 9: 15. https://doi.org/10.1186/s40413-016-0106-3; PMid:27134696 PMCid:PMC4836162
Snast I, Reiter O, Hodak E, Friedland R, Mimouni D, Leshem YA. (2018). Are biologics efficacious in atopic dermatitis? A systematic review and meta-analysis. Am J Clin Dermatol. 19 (2): 145-165. https://doi.org/10.1007/s40257-017-0324-7; PMid:29098604
Tam H, Calderon MA, Manikam L, Nankervis H, García Núñez I, Williams HC, Durham S, Boyle RJ. (2016). Specific allergen immunotherapy for the treatment of atopic eczema. Cochrane Database Syst Rev. 12; 2 (2): CD008774. PMID: 26871981; PMCID: PMC8761476. https://doi.org/10.1002/14651858.CD008774.pub2
Volosovets OP, Bolbot YuK, Beketova GV, Berezenko VS, Umanets TR et al. (2021). Allergic and non-allergic skin diseases in children of Ukraine: a retrospective study of the prevalence and incidence over the past 24 years. Medicni perspektivi. 26 (3): 188-196. https://doi.org/10.26641/2307-0404.2021.3.242319
Volosovets ОP, Beketova GV, Berezenko VS, Mityuryaeva IA, Volosovets TN, Pochinok TV. (2021). Dynamics of morbidity and prevalence of atopic dermatitis in children of Ukraine over the past 20 years: medical and environmental aspects. Pediatriia. Vostochnaia Yevropa. 2: 206-216. https://doi.org/10.34883/PI.2021.9.2.005
Yu N, Luo H, Liang D, Lu N. (2021). Sublingual immunotherapy in mite-sensitized patients with atopic dermatitis: a randomized controlled study. Postepy Dermatol Alergol. 38 (2): 69-74. https://doi.org/10.5114/ada.2021.104281; PMid:34408569 PMCid:PMC8362773
Zhong H, Deng X, Song Z, Darsow U, Chen W, Chen S, Luo N, Hao F. (2015). Immunological changes after ASIT in AD allergen-specific immunotherapy and their potential correlation with clinical response in patients with atopic dermatitis patients sensitized to house dust mite. J Eur Acad Dermatol Venereol. 29 (7): 1318-1324. https://doi.org/10.1111/jdv.12813; PMid:25376542
Zhou J, Chen S, Song Z. (2021). Analysis of the long-term efficacy and safety of subcutaneous immunotherapy for atopic dermatitis. Allergy Asthma Proc. 42 (2): e47-e54. https://doi.org/10.2500/aap.2021.42.200126; PMid:33685566 PMCid:PMC8133014
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Modern pediatrics. Ukraine
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The policy of the Journal “MODERN PEDIATRICS. UKRAINE” is compatible with the vast majority of funders' of open access and self-archiving policies. The journal provides immediate open access route being convinced that everyone – not only scientists - can benefit from research results, and publishes articles exclusively under open access distribution, with a Creative Commons Attribution-Noncommercial 4.0 international license (СС BY-NC).
Authors transfer the copyright to the Journal “MODERN PEDIATRICS. UKRAINE” when the manuscript is accepted for publication. Authors declare that this manuscript has not been published nor is under simultaneous consideration for publication elsewhere. After publication, the articles become freely available on-line to the public.
Readers have the right to use, distribute, and reproduce articles in any medium, provided the articles and the journal are properly cited.
The use of published materials for commercial purposes is strongly prohibited.
